Tecvayli (teclistamab-cqyv) / Genmab, J&J 
Welcome,         Profile    Billing    Logout  
 0 Diseases   1 Trial   1 Trial   2 News 


«12...6789101112131415161718»
  • ||||||||||  Darzalex IV (daratumumab) / J&J, teclistamab (JNJ-64007957) / Genmab, J&J
    Preclinical, Journal, PD(L)-1 Biomarker, IO biomarker:  Preclinical activity of JNJ-7957, a novel BCMAxCD3 bispecific antibody for the treatment of multiple myeloma, is potentiated by daratumumab. (Pubmed Central) -  Feb 7, 2021   
    JNJ-7957 effectively kills MM cells ex vivo, including those from heavily pretreated MM patients, whereby several components of the immunosuppressive BM microenvironment had only modest effects on its killing capacity. Our findings support the ongoing trial with JNJ-7957 as single agent, and provide the preclinical rationale for evaluating JNJ-7957 in combination with daratumumab in MM.
  • ||||||||||  Actemra IV (tocilizumab) / Roche, JW Pharma
    Journal, IO Biomarker:  T-cell redirecting bispecific antibodies targeting BCMA for the treatment of multiple myeloma. (Pubmed Central) -  Nov 25, 2020   
    Cytokine release syndrome is the most common adverse event, which can be adequately managed with tocilizumab or steroids...GPRC5D, CD38 and FcRH5), are also evaluated in early phase clinical trials. Such bispecific antibodies, targeting other antigens, may be given to patients with low baseline BCMA expression, disease with substantial heterogeneity in BCMA expression, following prior BCMA-targeted therapy, or combined with BCMA bispecific antibodies to prevent development of antigen escape.
  • ||||||||||  Darzalex IV (daratumumab) / J&J, talquetamab (JNJ-64407564) / J&J
    [VIRTUAL] Mechanisms of Resistance and Determinants of Response of the GPRC5D-Targeting T-Cell Redirecting Bispecific Antibody JNJ-7564 in Multiple Myeloma (Channel 11 (Virtual Meeting)) -  Nov 5, 2020 - Abstract #ASH2020ASH_4456;    
    We show that tumor-related factors, such as GPRC5D expression, as well as differences in the composition of the BM microenvironment, including E:T ratio, frequency of PD-1+ or HLA-DR+ T-cells or immune-suppressing Tregs or BMSCs, contribute to the variability in response to JNJ-7564. Our data indicate that strategies aiming at optimizing E:T ratio (e.g. induction therapy) or Treg depletion, may improve response to T-cell redirecting antibodies in MM.